Forty Seven is a clinical-stage immuno-oncology company developing therapies targeting cancer immune-evasion pathways based on technology licensed from Stanford University. Its lead program, 5F9, is a monoclonal antibody against CD47 designed to block the "don’t eat me" signal and is being evaluated in MDS, AML, NHL, ovarian cancer and colorectal cancer. Phase 1b data presented at ASCO and EHA showed an overall response rate (ORR) of 100% and a complete response (CR) rate of 55% among patients treated with 5F9 plus azacitidine in MDS. The company plans to initiate a single-arm, potentially registration‑enabling trial in higher‑risk MDS in Q1 2020 and believes a successful trial could support a BLA filing in Q4 2021. 5F9 has received FDA Fast Track designation for relapsed or refractory DLBCL and FL and Orphan Drug designation for AML from the FDA and EMA. Forty Seven has secured targeted support from The Leukemia & Lymphoma Society to accelerate 5F9’s clinical development in MDS. Forty Seven is a Menlo Park, California–based clinical-stage immuno-oncology company developing therapies targeting cancer immune evasion pathways licensed from Stanford University. Its lead program, Hu5F9-G4, is a monoclonal antibody against the CD47 receptor, a "don't eat me" signal that cancer cells use to avoid phagocytosis. Hu5F9-G4 is being evaluated in two Phase 1 clinical studies in patients with solid tumors and in patients with acute myeloid leukemia. The company is led by CEO Mark McCamish. Forty Seven raised $75M in a Series B financing to expand ongoing clinical trials and to initiate new trials combining its antibody with other immuno-oncology agents. The proceeds are intended to support advancement of its CD47 antibody programs into additional studies and combinations. Forty Seven is a clinical-stage immuno-oncology company focused on engaging phagocytic pathways to enhance anti-tumor efficacy and selectivity. The company licensed multiple immuno-oncology programs from Stanford, including rights to over 100 issued or pending U.S. and foreign patents covering Hu5F9-G4 and other immune checkpoint inhibitors and cancer-specific antibodies. Hu5F9-G4 is a humanized monoclonal antibody against CD47, a "don’t eat me" signal overexpressed on many tumors; in preclinical models it facilitated phagocytosis, elimination of cancer cells, and enhanced antibody-dependent cellular phagocytosis (ADCP) in combination therapy. Forty Seven is advancing Hu5F9-G4 in two ongoing clinical studies and plans additional clinical trials in 2016 to assess combination therapies, while also moving select preclinical programs toward IND. The company is led by CEO Jonathan MacQuitty and was co-founded by Irv Weissman, Ravi Majeti, Mark Chao and Jens Volkmer; senior scientific and medical leadership are also in place. It completed the first half of a committed $75M Series A to fund these clinical and preclinical programs.

Total raised

$160M

Funding rounds

3

Latest round

Equity

Latest activity

Aug 2019